Subtopic Deep Dive

← Macrophage Migration Inhibitory Factor

MIF in Tumor Angiogenesis and Cancer
Research Guide

What is MIF in Tumor Angiogenesis and Cancer?

Macrophage Migration Inhibitory Factor (MIF) promotes tumor angiogenesis by inducing VEGF expression, endothelial cell migration, and recruitment of tumor-associated macrophages in cancer progression.

MIF drives vascularization in tumors through proinflammatory signaling pathways (Calandra and Roger, 2003, 1758 citations). Studies show MIF activates Akt for cancer cell survival and inhibits p53 tumor suppression (Lue et al., 2007, 391 citations; Hudson et al., 1999, 639 citations). Preclinical models link high MIF to aggressive pancreatic and gastrointestinal cancers (Yang et al., 2016, 406 citations; Bandrés et al., 2009, 345 citations).

Curated Papers

Key Challenges

Why It Matters

MIF fuels tumor vascularization, enabling immune evasion and metastasis in cancers like pancreatic and ovarian (Yang et al., 2016; Hagemann et al., 2005). Antagonizing MIF reduces angiogenesis in preclinical models, supporting anti-angiogenic therapies (Lue et al., 2007). Tumor-associated macrophages recruited by MIF enhance invasiveness via NF-κB and JNK pathways, impacting survival rates (Hagemann et al., 2005, 435 citations). Targeting MIF-NR3C2 signaling offers therapeutic potential in MIF-overexpressing tumors (Yang et al., 2016).

Key Research Challenges

MIF Antagonist Efficacy

Developing MIF inhibitors that block tumor angiogenesis without disrupting innate immunity remains difficult (Calandra and Roger, 2003). Preclinical models show variable responses due to MIF's autocrine loops (Lue et al., 2007). Clinical translation faces hurdles from MIF's role in multiple cancer stages (Yang et al., 2016).

Heterogeneous TAM Recruitment

Tumor-associated macrophages vary by cancer type, complicating MIF-targeted interventions (Hagemann et al., 2005). MIF recruits pro-angiogenic subsets via NF-κB, but plasticity hinders prediction (Vannella and Wynn, 2016). MicroRNA regulation adds layers of control (Bandrés et al., 2009).

p53-MIF Signaling Crosstalk

MIF inhibits p53 activity, promoting survival, but pathway interactions are incompletely mapped (Hudson et al., 1999). Akt activation by MIF overlaps with other survival signals, challenging specificity (Lue et al., 2007). Quantifying contributions in vivo requires advanced models.

Essential Papers

Macrophage migration inhibitory factor: a regulator of innate immunity

Thierry Calandra, Thierry Roger · 2003 · Nature reviews. Immunology · 1.8K citations

A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity

James D. Hudson, M. A. Shoaibi, Roberta Maestro et al. · 1999 · The Journal of Experimental Medicine · 639 citations

p53 has a key role in the negative regulation of cell proliferation, in the maintenance of genomic stability, and in the suppression of transformation and tumorigenesis. To identify novel regulator...

Mechanisms of Organ Injury and Repair by Macrophages

Kevin M. Vannella, Thomas A. Wynn · 2016 · Annual Review of Physiology · 628 citations

Macrophages regulate tissue regeneration following injury. They can worsen tissue injury by producing reactive oxygen species and other toxic mediators that disrupt cell metabolism, induce apoptosi...

Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities

Yankai Wen, Joeri Lambrecht, Cynthia Ju et al. · 2020 · Cellular and Molecular Immunology · 627 citations

Functions of ROS in Macrophages and Antimicrobial Immunity

Marc Herb, Michael Schramm · 2021 · Antioxidants · 556 citations

Reactive oxygen species (ROS) are a chemically defined group of reactive molecules derived from molecular oxygen. ROS are involved in a plethora of processes in cells in all domains of life, rangin...

Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK

Thorsten Hagemann, Julia L. Wilson, Hagen Kulbe et al. · 2005 · The Journal of Immunology · 435 citations

Abstract Tumor-associated macrophages may influence tumor progression, angiogenesis and invasion. To investigate mechanisms by which macrophages interact with tumor cells, we developed an in vitro ...

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2

Shouhui Yang, Peijun He, Jian Wang et al. · 2016 · Cancer Research · 406 citations

Abstract Pancreatic cancers with aberrant expression of macrophage migration inhibitory factor (MIF) are particularly aggressive. To identify key signaling pathways that drive disease aggressivenes...

Reading Guide

Foundational Papers

Start with Calandra and Roger (2003) for MIF's immune regulation overview (1758 citations). Follow with Hagemann et al. (2005) on macrophage-driven invasiveness and Lue et al. (2007) on Akt-mediated survival.

Recent Advances

Yang et al. (2016) details MIF-NR3C2 in pancreatic cancer (406 citations). Bandrés et al. (2009) covers microRNA-451 regulation of MIF in GI cancers (345 citations).

Core Methods

Coculture assays for TAM-tumor interactions (Hagemann et al., 2005). Signaling pathway inhibitors for Akt/NF-κB (Lue et al., 2007). MicroRNA knockdown and overexpression (Bandrés et al., 2009).

How PapersFlow Helps You Research MIF in Tumor Angiogenesis and Cancer

Discover & Search

Research Agent uses searchPapers and citationGraph to map MIF-angiogenesis literature from Calandra and Roger (2003), revealing 1758 downstream citations on VEGF pathways. exaSearch uncovers preclinical antagonist studies; findSimilarPapers links Hagemann et al. (2005) to TAM recruitment papers.

Analyze & Verify

Analysis Agent applies readPaperContent to extract MIF-VEGF mechanisms from Yang et al. (2016), then verifyResponse with CoVe checks antagonist efficacy claims against 406 citing papers. runPythonAnalysis performs statistical meta-analysis of survival data from Lue et al. (2007); GRADE grading scores evidence strength for p53 inhibition (Hudson et al., 1999).

Synthesize & Write

Synthesis Agent detects gaps in MIF antagonist trials via contradiction flagging across Hagemann et al. (2005) and Bandrés et al. (2009). Writing Agent uses latexEditText, latexSyncCitations for review manuscripts, and latexCompile for figure-inclusive outputs; exportMermaid visualizes MIF-Akt-p53 pathways.

Use Cases

"Analyze survival data correlations from MIF overexpression papers in pancreatic cancer."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of hazard ratios from Yang et al., 2016) → matplotlib survival plots output.

"Draft LaTeX review on MIF-induced angiogenesis with citations."

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Calandra 2003, Hagemann 2005) → latexCompile → PDF with diagrams.

"Find code for MIF signaling simulations in tumor models."

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → executable models from similar MIF-VEGF dynamics.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ MIF-cancer papers: searchPapers → citationGraph → GRADE grading → structured report on angiogenesis mechanisms. DeepScan applies 7-step analysis with CoVe checkpoints to verify TAM recruitment claims from Hagemann et al. (2005). Theorizer generates hypotheses on MIF-p53 antagonists from Hudson et al. (1999) and Yang et al. (2016).

Try Doxa for MIF in Tumor Angiogenesis and Cancer Research

Frequently Asked Questions

What defines MIF's role in tumor angiogenesis?

MIF induces VEGF expression and endothelial migration, recruiting pro-angiogenic macrophages (Calandra and Roger, 2003; Hagemann et al., 2005).

What are key methods studying MIF in cancer?

In vitro coculture models assess macrophage-tumor interactions; signaling assays measure Akt and NF-κB activation (Hagemann et al., 2005; Lue et al., 2007).

What are foundational papers on this topic?

Calandra and Roger (2003, 1758 citations) reviews MIF immunity; Hagemann et al. (2005, 435 citations) links macrophages to invasiveness; Lue et al. (2007, 391 citations) details Akt survival pathway.

What open problems exist in MIF-cancer research?

Clinical efficacy of MIF antagonists; heterogeneity in TAM responses; precise mapping of MIF-p53 crosstalk in vivo (Yang et al., 2016; Hudson et al., 1999).